Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

2 1 1 1

What is this study about?

This clinical trial is focused on studying Triple Negative Breast Cancer, a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth. The study is specifically for patients who have residual disease after receiving initial treatment with chemotherapy and immunotherapy before surgery. The treatment being tested in this study involves the use of two medications: capecitabine and pembrolizumab. Capecitabine is a type of chemotherapy that is taken in the form of film-coated tablets, while pembrolizumab is an immunotherapy given as an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to evaluate how effective the combination of capecitabine and pembrolizumab is in preventing the return of cancer after surgery. Participants in the study will receive these medications after they have undergone surgery to remove the breast tumor. The study will monitor the participants over a period of time to see how well the treatment works in keeping the cancer from coming back. The study will also look at the overall survival of participants, which means the length of time they live after starting the study, and any side effects they may experience from the treatment.

Participants will be closely followed by the study team, and their health will be monitored regularly to ensure their safety and to gather information about the treatment’s effectiveness. The study aims to provide valuable insights into whether adding capecitabine to pembrolizumab can improve outcomes for patients with Triple Negative Breast Cancer who have residual disease after initial treatment. The study is expected to continue until 2028, with recruitment starting in 2024.

1 joining the study

Upon joining the study, the patient must have signed a written informed consent. If unable to do so, a trusted person can confirm the consent in writing.

The patient must have completed surgery for breast tumor removal and any affected lymph nodes.

2 initial assessment

The patient undergoes an assessment to ensure no complete pathological response to previous treatments, defined as RCB Class I, II, or III.

A tumor sample from the surgery is required for analysis.

3 pre-treatment requirements

The patient must have adequate organ and bone marrow function, confirmed by lab tests within 28 days before starting the trial.

Women of child-bearing potential must have a negative pregnancy test within 7 days before starting treatment.

4 treatment initiation

The treatment involves the administration of capecitabine and pembrolizumab.

Capecitabine is administered through infusion. The specific dosage and frequency are determined by the study protocol.

5 treatment duration

The treatment continues for a specified duration as outlined in the study protocol.

Regular monitoring and assessments are conducted to evaluate the patient’s response to the treatment.

6 follow-up and monitoring

The patient’s health and response to treatment are monitored throughout the study.

Safety and tolerability are assessed by tracking any adverse events.

7 study completion

The study aims to evaluate the efficacy of the treatment in improving invasive disease-free survival.

The study is expected to conclude by April 2028.

Who Can Join the Study?

The patient must have signed a written informed consent before any trial-specific procedures. If the patient cannot physically sign, a trusted person can confirm the patient’s consent in writing.
The patient must have Triple Negative Breast Cancer (TNBC) and have been treated with at least 6 cycles of standard neoadjuvant chemotherapy, including pembrolizumab, anthracyclines, and/or taxanes. Other drugs may be allowed after discussion, except capecitabine.
The patient must have had complete removal of the breast tumor(s) and any affected lymph nodes.
The patient must not have a complete pathological response, which means the cancer is classified as RCB Class I, II, or III based on local assessment.
A sample of the tumor from surgery, preserved in a specific way (formalin-fixed paraffin-embedded), must be available along with its histological report.
The patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or less. This is a scale that measures the patient’s ability to perform daily activities.
The patient must have adequate organ and bone marrow function, confirmed by lab tests done within 28 days before starting the trial.
The patient must be at least 18 years old.
The patient must have TNBC confirmed by tests showing HER2 negativity and less than 10% of cells stained for ER and PgR.
The patient must have recovered to at least grade 1 from any side effects of previous treatments, except for hair loss and certain hormone-related conditions that are controlled by medication.
The patient must have received at least one injection of pembrolizumab after surgery, either with or after radiotherapy.
The patient must have had breast surgery at least 2 weeks before starting the trial, and the surgical wound must be healed. The last pembrolizumab injection must have been at least 3 weeks before starting the trial.
Women who can become pregnant must have a negative pregnancy test within 7 days before starting the trial.
Women who can become pregnant and male patients must agree to use effective contraception from the time of the negative pregnancy test until 4 months after the last dose of study drugs.
The patient must be able and willing to attend study visits and follow procedures as outlined in the study protocol.
The patient must be affiliated with a Social Security System or equivalent.

Who Cannot Join the Study?

Patients who have not been diagnosed with Triple Negative Breast Cancer with remaining disease after receiving treatment before surgery.
Patients who have not received a combination of chemotherapy and immunotherapy before surgery.
Patients who are not within the specified age range for the study.
Patients who are not willing or able to follow the study procedures.
Patients who have other medical conditions that might interfere with the study treatment.
Patients who are pregnant or breastfeeding.
Patients who have participated in another clinical trial recently.
Patients who have allergies to the study medications.
Patients who have a history of other cancers that might affect the study results.
Patients who have serious infections or other health issues that could be worsened by the study treatment.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Centre Hospitalier Regional Et Universitaire De Brest	Brest	France
Institut De Cancerologie De Lorraine	Vandoeuvre Les Nancy	France
Oncopole Claudius Regaud	Toulouse	France
Centr Georges Francois Leclerc	Dijon	France
CHU Grenoble Alpes	La Tronche	France

Other Sites

Site Name	City	Country
Institut De Cancerologie Strasbourg Europe	STRASBOURG, Alsace	France
Centre Hospitalier De La Cote Basque	Bayonne	France
Centre Hospitalier Universitaire Amiens Picardie	Amiens	France
Polyclinique Bordeaux Nord Aquitaine	Bordeaux	France
Hopitaux Universitaires Pitie Salpetriere	Paris	France
Capio La Croix Du Sud	Quint-Fonsegrives	France
Institut Sainte Catherine	Avignon	France
Institut Godinot	Reims	France
Institut Curie – Site Saint-Cloud	Saint-Cloud	France
Centre Francois Baclesse	Caen	France
Centre Hospital Region Metz Thionville	Metz	France
Cxxpyc Hpwopfqukzl Er Uynlxvrahrhkc Dt Lnkminc	Limoges	France
Bgvfqvle Udkujwxnyw Hiwdqlzm Cnbqns	Besançon	France
Cxigwf Hzwjdtjkmht Rvwtpock Ufrnclyldtaxk Dd Tqorl	Tours	France
Cfetah Lsqc Bnddjn	Lyon	France
Iwlfpkio Pfurbyssmemeenw Cobjyw Cnplbn	Marseille	France
Cnxewq Ohbps Lgumeip	Lille	France
Incnqwxk Cpros	Paris	France

Trial status

Country	Status	Recruitment Start
France	Recruiting	01.10.2024

Trial locations

Investigated drugs:

Capecitabine is a medication used in this trial as a post-operative treatment. It is a type of chemotherapy that works by interfering with the growth of cancer cells, slowing their spread in the body. In this study, it is being evaluated for its effectiveness in improving survival rates in patients with Triple Negative Breast Cancer who have residual disease after initial treatment.

Pembrolizumab is an immunotherapy drug used in this trial. It helps the immune system recognize and attack cancer cells more effectively. In this study, it is combined with capecitabine to see if it can improve outcomes for patients with Triple Negative Breast Cancer who still have cancer remaining after initial treatments.

Investigated diseases:

Triple negative breast cancer

Triple Negative Breast Cancer – This is a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and the HER-2/neu gene. It is considered more aggressive and difficult to treat than other types of breast cancer. The disease often progresses quickly and is more likely to spread and recur. It is typically diagnosed in younger women and is more common in African American women. After initial treatment, such as chemotherapy, some patients may still have residual disease, which means that cancer cells remain in the body. This residual disease can lead to further progression if not managed effectively.

Trial ID:

2023-505291-30-01

Protocol code:

UC-BCG-2211, CAPPA

NCT ID:

NCT05973864

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?